GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.
GSK lifts sales guidance after “excellent” performance in 2024
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline.
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs.
GSK raises long-term guidance, announces buybacks
GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025. The company disclosed £8.
GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares
Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...
FTSE 100 giant GSK eyes more than £40bn in sales by 2031
Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...
London midday: Stocks slightly higher; GSK jumps on guidance upgrade
London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...
LONDON MARKET MIDDAY: FTSE 100 edges up, gold gleams and GSK shines
Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
FTSE 100 movers: GSK surges on guidance; DCC in the red
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
LONDON MARKET OPEN: GSK adds impetus but FTSE 100 struggles
The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...
pharmaphorum5d
Ex-GSK vaccine chief to lead new UK biotech Vicebio
GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...
Macau Business6h
GSK sees annual profit slide on Zantac drug fallout
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.